- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00336973
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
1 juli 2015 bijgewerkt door: Genentech, Inc.
A Phase IV Open-Label Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Raptiva (Efalizumab) in Adult Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects (18 years of age and older) with chronic moderate or worse plaque psoriasis who have had an inadequate response to treatment with an anti-TNF agent.
The study will consist of a screening period, a treatment period, and an observation period.
All subjects will begin in the screening period (the length of which is dependent on the previous anti-TNF agent treatment).
Approximately 100 eligible subjects will receive treatment from Day 0 through Day 168.
Studie Overzicht
Studietype
Ingrijpend
Inschrijving (Werkelijk)
73
Fase
- Fase 4
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Have chronic (6 months or greater) moderate or worse plaque psoriasis
- Have had an inadequate response to at least 12 weeks of treatment with an anti-TNF agent, where an inadequate response is defined as: PGA ratings of moderate (3), severe (4), or very severe (5), and BSA involvement of 5% or greater
- Be a candidate for systemic therapy or phototherapy in the opinion of the investigator
- Be naive to efalizumab treatment
- Weigh no more than 200 kg
- For women of childbearing potential, use a method of contraception acceptable to the investigator to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study and for 6 weeks after the last dose of efalizumab
Exclusion Criteria:
- Have a history of psoriatic arthritis that meets one of the following criteria: Is not controlled with non-steroidal anti-inflammatory drugs (NSAIDs);Requires the use of disease modifying antirheumatic drugs (DMARDs), including biologics while enrolled in the study; Please note that if, following enrollment, a subject requires treatment with a DMARD, study drug treatment should be discontinued and the subject should be moved into the observation period of the study. The subject should have the observation period assessments performed at the appropriate intervals as per the protocol
- Have a history of hypersensitivity to efalizumab or any of its components
- Are using any excluded therapy
- Are currently abusing alcohol or illegal drugs
- Have a history of or an ongoing uncontrolled serious bacterial, viral, fungal, or atypical mycobacterial infection. This includes diagnoses that required more than 2 weeks of therapy, such as endocarditis and osteomyelitis, which have been treated in the past 6 months. In addition, if the subject is currently receiving antibiotics, antivirals, or antifungals for an infection or for suppression or prophylaxis for any diagnosis, the subject will be excluded.
- Have any history of opportunistic infections (e.g., systemic fungal infections, parasites)
- Are seropositive for hepatitis B antigen, hepatitis C antibody, or human immunodeficiency virus (HIV). Subjects will undergo testing during screening, and any subjects who are seropositive for hepatitis B antigen, hepatitis C antibody, or HIV will be excluded.
- Have a history of active tuberculosis or are currently undergoing treatment for tuberculosis. A purified protein derivative (PPD) test will be performed at the screening visit. Subjects with a positive PPD test (not due to BCG vaccination) or chest x-ray will be excluded.
- Have the presence or history of malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled.
- Are pregnant or lactating women
- Have a diagnosis of hepatic cirrhosis, regardless of cause or severity
- Have a history of thrombocytopenia
- Have a history of clinically significant hemolytic or unexplained anemia
- Have been exposed to any experimental drugs or treatments within 30 days or 5 half-lives, whichever is longer, prior to the screening visit
- Have had any previous exposure to efalizumab
- Have been vaccinated with a live virus or live bacteria within the 14 days prior to the first dose of efalizumab
- Have any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug or would significantly interfere with the subject's ability to comply with the provisions of this protocol
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 1
|
Subcutane herhaalde dosis
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Proportion of Subjects With a Physician's Global Assessment (PGA) Rating of Clear (0), Almost Clear (1), or Mild (2)
Tijdsspanne: Day 84
|
The PGA scale used in this study was: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe
|
Day 84
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Proportion of Subjects With a PGA Rating of Clear (0), Almost Clear (1), or Mild (2)
Tijdsspanne: Day 168
|
The PGA scale used in this study was: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe
|
Day 168
|
Proportion of Subjects With a PGA Rating of Clear (0) or Almost Clear (1)
Tijdsspanne: Day 84
|
The PGA scale used in this study was: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe
|
Day 84
|
Proportion of Subjects With a PGA Rating of Clear (0) or Almost Clear (1)
Tijdsspanne: Day 168
|
The PGA scale used in this study was: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe
|
Day 168
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 mei 2006
Primaire voltooiing (Werkelijk)
1 februari 2008
Studieregistratiedata
Eerst ingediend
13 juni 2006
Eerst ingediend dat voldeed aan de QC-criteria
13 juni 2006
Eerst geplaatst (Schatting)
15 juni 2006
Updates van studierecords
Laatste update geplaatst (Schatting)
23 juli 2015
Laatste update ingediend die voldeed aan QC-criteria
1 juli 2015
Laatst geverifieerd
1 april 2009
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ACD3780g
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Psoriasis
-
ProgenaBiomeWervingPsoriasis | Psoriasis vulgaris | Psoriasis van de hoofdhuid | Psoriatische plaque | Psoriasis Universalis | Psoriasis gezicht | Psoriasis Nagel | Diffuse psoriasis | Psoriasis Punctata | Psoriasis palmaris | Psoriasis Circinata | Psoriasis annularis | Psoriasis genitale | Geografische psoriasisVerenigde Staten
-
Clin4allWervingPsoriasis van de hoofdhuid | Psoriasis Nagel | Psoriasis palmaris | Psoriasis genitale | Psoriasis PlantarisFrankrijk
-
Innovaderm Research Inc.VoltooidHoofdhuid Psoriasis | Pustuleuze palmoplantaire psoriasis | Niet-pustuleuze palmoplantaire psoriasis | Elleboog Psoriasis | OnderbeenpsoriasisCanada
-
AmgenVoltooidPsoriasis-type psoriasis | Psoriasis van het plaquetypeVerenigde Staten
-
UCB Biopharma S.P.R.L.VoltooidMatige tot ernstige psoriasis | Gegeneraliseerde pustuleuze psoriasis en erytrodermische psoriasisJapan
-
Janssen Pharmaceutical K.K.WervingGegeneraliseerde pustuleuze psoriasis | Erytrodermische PsoriasisJapan
-
Eli Lilly and CompanyVoltooidGegeneraliseerde pustuleuze psoriasis | Erytrodermische PsoriasisJapan
-
Centre of Evidence of the French Society of DermatologyWervingPsoriasis | Psoriasis vulgaris | Psoriasis van de hoofdhuid | Psoriatische plaque | Psoriasis Universalis | Psoriasis palmaris | Psoriatische erytrodermie | Psoriatische nagel | Psoriasis guttata | Psoriasis omgekeerd | Psoriasis PustuleuzeFrankrijk
-
TakedaWervingGegeneraliseerde pustuleuze psoriasis | Erytrodermische PsoriasisJapan
-
Bristol-Myers SquibbWervingPalmoplantaire Psoriasis | Genitale psoriasisVerenigde Staten, Duitsland, Spanje, Italië, Polen, Argentinië, Canada
Klinische onderzoeken op efalizumab
-
NYU Langone HealthGenentech, Inc.VoltooidHidradenitis suppurativaVerenigde Staten
-
Oregon Health and Science UniversityVoltooidDermatitis, atopisch
-
Genentech, Inc.Voltooid
-
Genentech, Inc.Voltooid
-
Merck KGaA, Darmstadt, GermanyVoltooidMatige tot ernstige psoriasisZwitserland
-
Norwegian University of Science and TechnologyBeëindigdPlaque PsoriasisNoorwegen
-
Washington University School of MedicineGenentech, Inc.VoltooidLichen planus, oraalVerenigde Staten
-
Merck KGaA, Darmstadt, GermanyVoltooidPsoriasis | Kandidaten voor systemische therapie voor psoriasisZwitserland